Health Canada warns doctors not to start this prescription medication

• The FDA has approved mFLUSIVA, the first flu vaccine to utilize mRNA technology similar to that used in COVID-19 vaccines. • Clinical trial data published in The New England Journal of Medicine showed that 2% of mFLUSIVA recipients developed flu-like illnesses, compared to 2.8% for those receiving a standard-dose vaccine.

• The U.S. Food and Drug Administration (FDA) has officially approved a new mRNA-based vaccine designed to combat influenza. • Despite this milestone, experts caution that the approval does not necessarily signal a broad government embrace of mRNA technology for all vaccines.

• A new oral antiviral drug called Xocova has been developed to prevent COVID-19 infections in individuals who have been exposed to the virus. • Unlike treatments administered after symptoms appear, Xocova is specifically designed as a post-exposure prophylactic to reduce the likelihood of contracting the illness.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies, designed as a treatment for the Ebola virus. • The trial will take place in the Democratic Republic of Congo to combat the largest and most rapidly expanding Ebola outbreak on record.

• A new study indicates that higher protein intake during the first trimester of pregnancy is linked to a lower risk of small birth size. • Separately, researchers analyzed data from 296,372 adults in the UK Biobank to determine if long-term exposure to residential night-time light (NTL) accelerates biological aging.

• NanoViricides, Inc. (NASDAQ:NNVC) has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 oral gummies designed to treat the Bundibugyo Ebola virus. • The trial addresses an urgent need for effective antiviral drugs amid a current outbreak in the Democratic Republic of Congo (DRC).

• The FDA has approved the first mRNA-based influenza vaccine, reversing a previous decision earlier this year to decline the application's review. • The approval covers adults aged 50 to 64, while those aged 65 and older have received accelerated approval.

• The CDC, FDA, and state public health officials are investigating a multistate outbreak of Salmonella Javiana infections reported in August 2026. • Epidemiological data has linked the current outbreak to the consumption of jalapenos.

• The FDA has authorized Moderna’s mFlusiva, marking the first mRNA-based flu vaccine approved for use in older adults. • Separately, U.S. health officials are reviewing the nation's measles elimination status following 38 new outbreaks in 2026.

• The FDA has approved a new engineered viral immunotherapy designed specifically for patients suffering from treatment-resistant advanced melanoma. • This approval provides a critical new therapeutic option for cancer patients who have failed to respond to existing standard-of-care treatments.

• The FDA has approved the first-of-its-kind mRNA-based flu vaccine specifically for adults aged 50 and older. • This approval follows a severe 2024-25 flu season, which the CDC estimates resulted in approximately 45,000 deaths.

• The CDC has expanded the largest known cyclosporiasis outbreak to 15 states, adding Arkansas, Iowa, Missouri, Nebraska, New Hampshire, and North Carolina to the list. • Health officials have traced the illnesses to shredded iceberg lettuce sourced from central Mexico.